Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
FDA approves first generic florfenicol–flunixin injectable (nixiFLOR) for bovine respiratory disease
The FDA has approved nixiFLOR, the first generic florfenicol-flunixin injectable, for treatment of bovine respiratory disease and control of associated fever in beef and nonlactating dairy cattle.
LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm ...
News-Medical.Net on MSN
Peptide-based platform marks a major step toward needle-free diabetes care
For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...
AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...
Live Science on MSN
IVF hormones could be delivered with painless 'microneedle' patch someday, early study hints
Scientists are developing a microneedle patch that they hope could someday simplify IVF hormone delivery. They've tested it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results